Summary & Overview

HCPCS J7667: Metaproterenol Inhalation Solution, Compounded 10 mg

HCPCS Level II code J7667 covers metaproterenol sulfate inhalation solution in a compounded, concentrated form, reported per 10 milligrams. This code identifies a pharmacy-prepared bronchodilator solution used for inhalation therapy in patients with obstructive airway disease. Nationally, accurate use of J7667 matters for consistent drug reporting, payer adjudication, and tracking utilization of compounded respiratory therapeutics.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary addresses how these payers typically encounter this code in outpatient and ambulatory settings and in pharmacy-dispensed compounded preparations.

Readers will find benchmarks for expected use settings, coding context for compounded inhalation drugs, and clinical context about when a compounded metaproterenol solution may be used. The publication also outlines documentation and billing considerations relevant to national payers, common sites of service, and implications for claims processing. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7667HCPCS Level IImetaproterenolcompounded inhalation solutionpharmacy-dispensed drugsrespiratory therapyoutpatient billingdrug codingambulatory carehospital outpatient

Billing Code Overview

HCPCS Level II code J7667 describes metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams. This code represents a compounded bronchodilator solution prepared for inhalation use, intended to provide bronchodilation therapy for patients with obstructive airway conditions.

Service type: drug administration / pharmacy-dispensed compounded inhalation solution

Typical site of service: outpatient infusion/ambulatory care settings, hospital outpatient departments, and specialty pharmacy dispensing for inhalation therapy

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric patient presenting to an outpatient pulmonology clinic, emergency department, or infusion/compounding pharmacy with acute bronchospasm from asthma, chronic obstructive pulmonary disease (COPD) exacerbation, or reactive airways disease who requires an inhaled bronchodilator that is not available as a standard commercial preparation. The compounded concentrated inhalation solution J7667 (metaproterenol sulfate, per 10 mg) is prepared by a licensed compounding pharmacy and delivered for administration via nebulizer in-clinic or provided to the patient for home nebulizer use when a patient-specific concentration, preservative-free formulation, or shortage of commercial product necessitates compounding.

Typical clinical workflow:

Patient triage and assessment for bronchospasm severity with vital signs and respiratory exam.
Physician orders inhaled bronchodilator therapy; if commercial metaproterenol solution is unavailable or a custom concentration is required, the prescriber writes a prescription for a compounded metaproterenol inhalation solution, documented with concentration, volume, route (nebulized inhalation), and quantity.
The prescription is transmitted to a licensed compounding pharmacy. The pharmacy compounds J7667 per USP <797>/<795> sterile/nonsterile compounding standards as applicable, verifies concentration, performs quality checks, and labels for nebulized use.
Product is returned to clinic or dispensed to patient. If administered in-clinic, nursing documents lot, dose, time, route, and patient response. For home use, counseling on nebulizer technique and storage is provided.
Billing: The compounding pharmacy or facility bills HCPCS Level II code J7667 per 10 mg unit, applying clinically appropriate modifiers to indicate circumstances (e.g., increased procedural services, reduced services, or payer-specific indicators). Clinical documentation supports the medical necessity, dosing, and whether administration occurred on-site or medication was dispensed for home use.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier / default	Use when no additional modifier is applicable and claim is submitted in standard form.
`22`	Increased procedural services	Use when preparation required substantially greater work or time than typical (e.g., complex sterile compounding beyond standard concentration).
`23`	Unusual anesthesia	Not typically used for inhalation solutions; generally not applicable to `J7667`.
`52`	Reduced services	Use when the compounded product or service delivered is partially reduced or only partially performed.
`53`	Discontinued procedure	Use if compounding was initiated but aborted prior to completion for documented clinical reasons.
`54`	Surgical care only	Not applicable for medication compounding; rarely used.
`55`	Postoperative management only	Not applicable for this code.
`56`	Preoperative management only	Not applicable for this code.
`62`	Two surgeons	Not applicable to pharmacy compounding or single-provider respiratory care.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare reporting	Use when a non-physician practitioner provided the clinical service related to medication administration under Medicare rules.
`CO`	Workers' compensation jurisdictional exclusion	Use when claim is related to workers' compensation and payor requires this modifier.
`CQ`	Service delivered under CGS/Carrier specific program (example)	Use when payer requires a CQ indicator for specific program reporting (payer-dependent).
`FX`	Special payment indicator for specific carriers	Use only when required by a given payer to flag special billing circumstances.
`FY`	Claim is subject to a public health emergency exception	Use during declared public health emergencies when payer guidance requires this indicator.
`QX`	Anesthesiologist medically directs CRNA	Not applicable to compounding medication; typically not used.
`QY`	Anesthesiologist personally performed regional anesthesia	Not applicable.
`SH`	Speech-language pathology services	Not applicable.
`TG`	Transport records generated	Use when transportation or transfer services related to medication administration are billed and payer requires TG.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Pulmonary Disease	Pulmonologists commonly order nebulized bronchodilators and manage dosing for airway diseases.
`363L00000X`	Pharmacy	Compounding pharmacists perform preparation, quality assurance, and dispensing of `J7667`.
`103T00000X`	Emergency Medicine	Emergency physicians commonly request nebulized bronchodilator therapy for acute bronchospasm.
`363A00000X`	Clinical Pharmacology	Clinical pharmacists involved in medication therapy management and dosing oversight for compounded inhalation solutions.
`173E00000X`	Respiratory Care	Respiratory therapists administer nebulized treatments in-clinic or inpatient settings.

ICD-10 Code	Description	Clinical Relevance
`J45.909`	Unspecified asthma, uncomplicated	Asthma with acute bronchospasm is a primary indication for nebulized bronchodilator therapy using compounded metaproterenol.
`J45.901`	Unspecified asthma with (acute) exacerbation	Acute exacerbations often require nebulized bronchodilators administered in-clinic or prescribed for home nebulizer use.
`J44.1`	Chronic obstructive pulmonary disease with (acute) exacerbation	COPD exacerbations may require nebulized short-acting bronchodilators when rapid bronchodilation is needed.
`J44.9`	Chronic obstructive pulmonary disease, unspecified	COPD patients with baseline bronchospasm may receive inhaled bronchodilators.
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Severe bronchospasm causing respiratory compromise may necessitate nebulized bronchodilator therapy as part of stabilization.

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction (e.g., nebulizer therapy)	Commonly performed when `J7667` is administered via nebulizer in-clinic; documents the inhalation treatment session.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	May be provided in the same visit for patients with COPD/asthma as part of comprehensive respiratory care (behavioral counseling alongside medication management).
`94664`	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	Used when a patient is taught nebulizer technique for use of compounded `J7667` delivered for home use.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate severity	Typical E/M visit code when a clinician evaluates bronchospasm and prescribes a compounded inhalation solution.
`99070`	Supplies and materials provided by the physician over and above those normally included with the service, (e.g., medication not otherwise specified)	May be used by facilities to bill for supplies or the compounded medication when payer allows; many payers prefer `J`-code billing for the drug itself.

OpenPayer